- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT07947160
High-flow Nasal Oxygenation in Obese Patients During Colonoscopy: a Randomized Controlled Trial (COCOON) (COCOON)
High-flow Nasal Oxygenation in Obese Patient During Colonoscopy: a Randomized Controlled Trial: the COCOON Trial
The goal of this clinical trial is to determine whether high-flow oxygen therapy (HFOT) is more effective than conventional oxygen therapy (COT) in reducing episodes of intraoperative oxygen desaturation (oxygen saturation [SpO2] ≤ 90%) during colonoscopy under general anesthesia in adults with a body mass index (BMI) of 30 kg/m² or higher.
The main question it aims to answer is:
Does high-flow oxygen therapy reduce the occurrence of intraoperative oxygen desaturation compared with conventional oxygen therapy during colonoscopy under general anesthesia? Researchers will compare high-flow oxygen therapy with conventional oxygen therapy to determine whether high-flow oxygen therapy reduces the occurrence of intraoperative oxygen desaturation.
Participants will:
Be screened during their anesthesia consultation between 60 days and 48 hours before the scheduled colonoscopy.
Be randomly assigned (1:1) to receive either conventional oxygen therapy or high-flow oxygen therapy. Receive standard monitoring and 3 minutes of pre-oxygenation according to their assigned treatment group.
Undergo colonoscopy under general anesthesia while breathing spontaneously. Be monitored for oxygen desaturation during the procedure. Have ventilatory and hemodynamic data recorded during the procedure and collected immediately after the colonoscopy.
The study will include adults scheduled for a colonoscopy at Bichat-Claude Bernard Hospital, Beaujon Hospital, or Louis Mourier Hospital.
Tutkimuksen yleiskatsaus
Tila
Ehdot
Yksityiskohtainen kuvaus
Prospective, multicentre, controlled, randomized, parallel-group superiority trial with a 1:1 allocation ratio, with participants blinded to the oxygen treatment received, comparing high-flow oxygen therapy (HFOT) with conventional oxygen therapy (COT) delivered through an oxygen mask. The study aims to determine whether HFOT is more effective than COT in preventing intraoperative oxygen desaturation during colonoscopy under general anesthesia in participants with a body mass index (BMI) of 30 kg/m² or higher.
Adults with a body mass index (BMI) of 30 kg/m² or higher who are scheduled to undergo a colonoscopy at Bichat-Claude Bernard Hospital, Beaujon Hospital, or Louis Mourier Hospital.
After written informed consent has been obtained, participants will be randomized by the study investigators to one of the two treatment groups: conventional oxygen therapy (COT); high-flow oxygen therapy (HFOT).
A computer-generated randomization list with a 1:1 allocation ratio and variable block sizes will be prepared by a statistician from the URC Paris Nord Secteur Ouest, in accordance with the sponsor's procedures. Allocation will be concealed, as the randomization list will not be accessible to the study team. The list will be directly integrated into CleanWEB™, a secure, centralized, 24- hour Internet platform, which will also be used for the electronic case report form (eCRF).
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Opiskeluyhteys
- Nimi: Jules STERN
- Puhelinnumero: +33140258080
- Sähköposti: jules.stern@aphp.fr
Tutki yhteystietojen varmuuskopiointi
- Nimi: Ines CHIBANE, +33140257961
- Sähköposti: ines.chibane@aphp.fr
Opiskelupaikat
-
-
-
Clichy, Ranska, 92110
- Hôpital Beaujon, département d'anesthésie-réanimation, 100 boulevard du Général Leclerc
-
Ottaa yhteyttä:
- Stéphanie SIGAUT, Principal Investigator
-
Colombes, Ranska, 92700
- Hôpital Louis Mourier, département d'anesthésie-réanimation, 178 rue des Renouillers
-
Paris, Ranska, 75018
- Hôpital Bichat-Claude Bernard, département d'anesthésie-réanimation, 46 rue Henri Huchard
-
Ottaa yhteyttä:
- Jules STERN, Principal Investigator
- Puhelinnumero: +33140258080
- Sähköposti: jules.stern@aphp.fr
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- Age 18 years or older.
- Body mass index (BMI) of 30 kg/m² or higher.
- Scheduled to undergo a colonoscopy under general anesthesia with spontaneous breathing at Bichat-Claude Bernard Hospital, Beaujon Hospital, or Louis Mourier Hospital.
- Affiliated with a social security scheme.
- Free, informed and written consent signed.
Exclusion Criteria:
-
Colonoscopy in a participant at high risk of aspiration requiring orotracheal intubation, defined by at least one of the following:
- Symptomatic or severe gastroesophageal reflux disease, notably with frequent regurgitation (≥ 2 episodes per week), mainly occurring in the supine position;
- Hiatal hernia;
- History of bariatric surgery (sleeve gastrectomy, gastric bypass);
- Neurodegenerative disease requiring airway protection during colonoscopy.
-
Emergency colonoscopy.
-
Chronic respiratory failure.
-
Severe heart failure.
-
Allergy to propofol.
-
Pregnant or breastfeeding woman.
-
Adult under legal protection (guardianship or curatorship).
-
Beneficiary of State Medical Aid (Aide Médicale de l'État, AME).
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Ennaltaehkäisy
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Yksittäinen
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Active Comparator: Conventional oxygen therapy
Participants assigned to the conventional oxygen therapy group will receive 100% oxygen at 6 L/min through an oxygen capnography mask during the 3-minute pre-oxygenation period and throughout the procedure. After pre-oxygenation, propofol will be administered by target-controlled intravenous infusion, with an initial target concentration of 2 µg/mL. The anesthetist may adjust the target concentration to achieve deep sedation according to American Society of Anesthesiologists (ASA) criteria. The colonoscopy will be performed while participants breathe spontaneously. |
100% oxygen delivered at a flow rate of 6 L/min through an oxygen capnography mask, during the 3-minute pre-oxygenation period and throughout the colonoscopy performed under general anesthesia (propofol target-controlled infusion) with spontaneous breathing.
Muut nimet:
|
|
Kokeellinen: High-flow oxygen therapy
Participants assigned to the high-flow oxygen therapy group will receive 100% oxygen at 50 L/min through an Optiflow® system (Fisher & Paykel Healthcare) during the 3-minute pre-oxygenation period and throughout the procedure. After pre-oxygenation, propofol will be administered by target-controlled intravenous infusion, with an initial target concentration of 2 µg/mL. The anesthetist may adjust the target concentration to achieve deep sedation according to American Society of Anesthesiologists (ASA) criteria. The colonoscopy will be performed while participants breathe spontaneously. |
100% oxygen delivered at a flow rate of 50 L/min through an Optiflow® high-flow nasal system (Fisher & Paykel Healthcare), during the 3-minute pre-oxygenation period and throughout the colonoscopy performed under general anesthesia (propofol target-controlled infusion) with spontaneous breathing.
Muut nimet:
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Number of participants with at least one episode of oxygen desaturation (SpO2 ≤ 90%) during the procedure
Aikaikkuna: From the start to the end of the procedure (Day 0)
|
Oxygen desaturation is defined as a peripheral oxygen saturation (SpO2) ≤ 90%, regardless of its duration, measured by continuous pulse oximetry during the colonoscopy performed under general anesthesia. |
From the start to the end of the procedure (Day 0)
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Total number of episodes of oxygen desaturation (SpO₂ ≤ 90%) during the procedure
Aikaikkuna: From the start to the end of the procedure (Day 0)
|
Number of desaturation episodes (SpO2 ≤ 90%) per participant, determined from continuously recorded pulse oximetry data. |
From the start to the end of the procedure (Day 0)
|
|
Cumulative duration of oxygen desaturation episodes (SpO2 ≤ 90%) relative to the total duration of the procedure
Aikaikkuna: From the start to the end of the procedure (Day 0)
|
Total time (in seconds) spent with SpO2 ≤ 90%, divided by the total duration of the procedure, i.e. the fraction of procedure time spent in desaturation (between 0 and 1), determined from continuously recorded pulse oximetry data. |
From the start to the end of the procedure (Day 0)
|
|
Occurrence of an episode of hypotension, defined as systolic blood pressure (SBP) < 100 mmHg, during the procedure
Aikaikkuna: From the start to the end of the procedure (Day 0)
|
Determined from continuously recorded non-invasive blood pressure data. |
From the start to the end of the procedure (Day 0)
|
|
Occurrence of an episode of severe bradycardia, defined as heart rate < 40 beats/minute, during the procedure
Aikaikkuna: From the start to the end of the procedure (Day 0)
|
Determined from continuously recorded heart rate data. |
From the start to the end of the procedure (Day 0)
|
|
Use of orotracheal intubation during the procedure
Aikaikkuna: From the start to the end of the procedure (Day 0)
|
Collected from the medical record and reported in the eCRF. |
From the start to the end of the procedure (Day 0)
|
|
Occurrence of a cardiac arrest during the procedure
Aikaikkuna: From the start to the end of the procedure (Day 0)
|
Cardiorespiratory arrest, collected from the medical record and reported in the eCRF |
From the start to the end of the procedure (Day 0)
|
Yhteistyökumppanit ja tutkijat
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Arvioitu)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- APHP251722
- 2026-A00471-50 (Muu tunniste: IDRCB)
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .